Clinical trial · Interventional
Natrecor in Pulmonary Hypertension
Phase IV, Open Labeled Study to Test the Effectiveness of Nesiritide in Reversing Pulmonary Hypertension in Patients Who Will be Undergoing CardioThoracic Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual.
Summary
Brief summary (as posted)
The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cardiothoracic Surgery | — | UNRESOLVED | — |
| Lung Disease | — | UNRESOLVED | — |
| Pulmonary Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nesiritide (Natrecor) | Drug | — | UNRESOLVED |
| Right Heart Catheterization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Nesiritide
- description
- Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
- interventionNames
- Drug: Nesiritide (Natrecor)
- Procedure: Right Heart Catheterization
Primary outcomes (1)
- measure
- Number Patients with 20% reduction in mean pulmonary arterial (PA) pressure to measure pulmonary hypertension (PHTN)
- timeFrame
- Baseline and 15 and 30 minutes after end of procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Ages 18 to 85 years old. 2. Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's). 3. PHTN documented by Doppler Echocardiography ( Done with in last 30 days) 4. Must be able to give an informed consent. Exclusion Criteria: 1. Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) \<90). 2. Active infection or sepsis as defined by fever and need for IV antibiotics. 3. Creatinine greater than 3.0 mg/dl 4. Significant valvular disease as a cause for the PHTN. 5. Severe Thrombocytopenia (as defined by platelets less than 20,000 or INR \> 1.6. 6. Left Ventricle Ejection Fraction (LVEF) \<40% (must be done with in the last 30 days prior to signing consent). 7. Hypersensitivity to nesiritide or any of it's components.
References
Publications (0)
Data not yet available